

**Clinical Policy: Denosumab (Prolia, Xgeva), Denosumab-bbdz (Jubbonti, Wyost), Denosumab-dssb (Ospomyv, Xbryk), Denosumab-bmwo (Stoboclo, Osenvelt), Denosumab-bnht (Bomyntra, Conexxence)**

Reference Number: CP.PHAR.58

Effective Date: 03.01.11

Last Review Date: 02.25

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Denosumab (Prolia<sup>®</sup>, Xgeva<sup>®</sup>) and its biosimilars, denosumab-bbdz (Jubbonti<sup>®</sup>, Wyost<sup>®</sup>), denosumab-bmwo (Stoboclo<sup>®</sup>, Osenvelt<sup>®</sup>), denosumab-bnht (Bomyntra<sup>®</sup>, Conexxence<sup>®</sup>), and denosumab-dssb (Ospomyv<sup>™</sup>, Xbryk<sup>™</sup>), are receptor activators of nuclear factor kappa-B ligand inhibitor.

**FDA Approved Indication(s)**

Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, and denosumab-dssb are indicated:

- For the treatment of postmenopausal women with osteoporosis (PMO) at high risk for fracture\*, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidences of vertebral, nonvertebral, and hip fractures.
- For the treatment to increase bone mass in men with osteoporosis at high risk for fracture\*, or patients who have failed or are intolerant to other available osteoporosis therapy.
- For the treatment of glucocorticoid-induced osteoporosis (GIO) in men and women at high risk of fracture\* who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to  $\geq 7.5$  mg of prednisone and expected to remain on glucocorticoids for  $\geq 6$  months.
- For treatment to increase bone mass in men at high risk for fracture\* receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures.
- For treatment to increase bone mass in women at high risk for fracture\* receiving adjuvant aromatase inhibitor therapy for breast cancer.

---

*\*High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.*

Xgeva, Bomyntra, Osenvelt, Wyost, Xbryk, and denosumab-bnht are indicated:

- For the prevention of skeletal-related events in patients with multiple myeloma (MM) and in patients with bone metastases from solid tumors.
- For the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
- For the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

**Index**

**I. Initial Approval Criteria**

- A.** Osteoporosis (*Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb*)
- B.** Prostate/Breast Cancer - Fracture Prevention (*Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb*)
- C.** Multiple Myeloma or Solid Tumor (*Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht*)
- D.** Giant Cell Tumor of Bone (*Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht*)
- E.** Hypercalcemia of Malignancy (*Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht*)
- F.** Systemic Mastocytosis (off-label) (*Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht*)
- G.** Other diagnoses/indications

**II. Continued Therapy**

- A.** All Indications in Section I (*Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, denosumab-bnht, or denosumab-dssb*)
- B.** Other diagnoses/indications

**III. Diagnoses/Indications for which coverage is NOT authorized**

**IV. Appendices/General Information**

**V. Dosage and Administration**

**VI. Product Availability**

**VII. References**

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Bomynta, Conexxence, Jubbonti, Osenvelt, Ospomyv, Prolia, Stoboclo, Wyost, Xbryk, Xgeva, denosumab-bnht, and denosumab-dssb are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Osteoporosis** (must meet all):

- 1. Request is for Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb;
- 2. Diagnosis of PMO, GIO, or male osteoporosis and one of the following (a or b):
  - a. Member is at very high risk for fracture as evidenced by one of the following (i, ii, or iii):
    - i. Recent osteoporotic fracture (within the past 12 months);
    - ii. Bone mineral density (BMD) T-score at hip or spine  $\leq -3.0$  (*see Appendix F*);
    - iii. BMD T-score at hip or spine  $\leq -2.5$  AND major osteoporotic fracture (i.e., hip, spine, forearm, wrist, humerus) (*see Appendix F*);

- b. Member has completed a 3-year trial of bisphosphonate therapy\* (*see Appendix B; generic alendronate is preferred*) at up to maximally indicated doses unless one of the following (i-v):
    - i. All bisphosphonates are contraindicated;
    - ii. Clinically significant adverse effects are experienced to both IV and PO formulations (*see Appendix D*);
    - iii. Member has experienced a loss of BMD while receiving bisphosphonate therapy;
    - iv. Member has experienced a lack of BMD increase after  $\geq 12$  months of bisphosphonate therapy;
    - v. Member experienced an osteoporotic fracture or fragility fracture while receiving bisphosphonate therapy;
- \*Prior authorization may be required for bisphosphonates.
3. Age  $\geq 18$  years or documentation of closed epiphyses on x-ray;
  4. Prolia, Conexence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb are not prescribed concurrently with Xgeva, Bomynta, Osenvelt, Wyost, or Xbryk;
  5. Dose does not exceed 60 mg every 6 months.

**Approval duration:**

**Medicaid/HIM** – 12 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**B. Prostate/Breast Cancer - Fracture Prevention** (must meet all):

1. Request is for Prolia, Conexence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb;
2. Diagnosis of one of the following (a or b):
  - a. Prostate cancer, and member is receiving ADT (e.g., leuprolide (Lupron<sup>®</sup>), bicalutamide (Casodex<sup>®</sup>) or nilutamide (Nilandron<sup>®</sup>);
  - b. Breast cancer, and member is receiving adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitors such as anastrozole (Arimidex<sup>®</sup>), exemestane (Aromasin<sup>®</sup>) or letrozole (Femara<sup>®</sup>);
3. Member does not have bone metastasis;
4. Prescribed by or in consultation with an oncologist;
5. Age  $\geq 18$  years or documentation of closed epiphyses on x-ray;
6. Member meets one of the following (a, b, or c):
  - a. For breast cancer, failure of zoledronic acid\* (Zometa) or pamidronate\*, at up to maximally indicated doses unless clinically significant adverse effects are experienced or both are contraindicated (*see Appendices B and D*);  
\*Prior authorization may be required.
  - b. For prostate cancer, failure of zoledronic acid\* (Zometa) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced (*see Appendices B and D*);  
\*Prior authorization may be required.
  - c. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix E*);

7. Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb are not prescribed concurrently with Xgeva, Bomynta, Osenvelt, Wyost, or Xbryk;
8. Dose does not exceed 60 mg every 6 months.

**Approval duration:**

**Medicaid/HIM** – 12 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**C. Multiple Myeloma or Solid Tumor (must meet all):**

1. Request is for Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht;
2. Diagnosis of one of the following (a or b):
  - a. MM, and member is receiving or initiating therapy (e.g., chemotherapy, transplant) for symptomatic disease;
  - b. Bone metastasis secondary to solid tumor (e.g., breast, kidney, lung, prostate, thyroid);
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
5. For indications other than prostate or breast cancer, member meets one of the following (a or b):
  - a. Failure of zoledronic acid\* (Zometa) or pamidronate\* at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated (*see Appendices B and D*);  
*\*Prior authorization may be required.*
  - b. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix E*);
6. Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht are not prescribed concurrently with Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, or denosumab-dssb;
7. Dose does not exceed 120 mg every 4 weeks.

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**D. Giant Cell Tumor of Bone (must meet all):**

1. Request is for Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht;
2. Diagnosis of giant cell tumor of bone that is characterized as one of the following (a or b):
  - a. Metastatic or unresectable disease;
  - b. Localized disease, and Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht are prescribed as a single agent or in combination with radiation therapy;
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
5. Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht are not prescribed concurrently with Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, or denosumab-dssb;

6. Dose does not exceed 120 mg every 4 weeks plus 120 mg on days 8 and 15 of first month of therapy.

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**E. Hypercalcemia of Malignancy (must meet all):**

1. Request is for Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht;
2. Diagnosis of hypercalcemia of malignancy;
3. Prescribed by or in consultation with an oncologist;
4. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
5. Albumin-corrected calcium  $>$  12.5 mg/dL despite IV bisphosphonate therapy in the last 30 days (*see Appendix B*);  
*\*Prior authorization may be required.*
6. Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht are not prescribed concurrently with Prolia, Conexence, Jubbonti, Ospomyv, Stoboclo, or denosumab-dssb;
7. Dose does not exceed 120 mg every 4 weeks plus 120 mg on days 8 and 15 of first month of therapy.

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**F. Systemic Mastocytosis (off-label) (must meet all):**

1. Request is for Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht;
2. Diagnosis of systemic mastocytosis;
3. Member has osteopenia or osteoporosis with bone pain;
4. Prescribed by or in consultation with an oncologist;
5. Age  $\geq$  18 years or documentation of closed epiphyses on x-ray;
6. Member meets one of the following (a or b):
  - a. Failure of zoledronic acid\* (Zometa) or pamidronate\* at up to maximally indicated doses unless clinically significant adverse effects are experienced or both are contraindicated (*see Appendices B and D*);  
*\*Prior authorization may be required.*
  - b. Request is for the treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix E*);
7. Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht are not prescribed concurrently with Prolia, Conexence, Jubbonti, Ospomyv, Stoboclo, or denosumab-dssb;
8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).\*

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**G. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I (must meet all):**

1. Member meets one of the following (a, b, or c):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
  - c. Documentation supports that member is currently receiving Prolia, Xgeva, Conexxence, Jubbonti, Wyost, Bomynta, Ospomyv, Xbryk, Osenvelt, Stoboclo, denosumab-bnht, or denosumab-dssb for a covered cancer-related indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed (a or b):
  - a. Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, or denosumab-dssb: 60 mg every 6 months;
  - b. Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, or denosumab-bnht: 120 mg every 4 weeks or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).\*

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration:**

**Medicaid/HIM** – 12 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):



- a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

### III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

### IV. Appendices/General Information

#### Appendix A: Abbreviation/Acronym Key

ADT: androgen deprivation therapy  
BMD: bone mineral density  
CKD-MBD: chronic kidney disease-mineral bone disorder

FDA: Food and Drug Administration  
GIO: glucocorticoid-induced osteoporosis  
MM: multiple myeloma  
PMO: postmenopausal osteoporosis

#### Appendix B: Therapeutic Alternatives

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<b>IV bisphosphonates</b>		
ibandronate (Boniva <sup>®</sup> )	Treatment: PMO Hypercalcemia of malignancy ( <i>off-label</i> )	Varies <i>See prescribing information and compendia for dosing.</i>
zoledronic acid (Reclast <sup>®</sup> ; Zometa <sup>®</sup> )	<u>Reclast:</u> Treatment/prevention: PMO, GIO Treatment: male osteoporosis <u>Zometa:</u> MM Bone metastasis from solid tumors Hypercalcemia of malignancy Systemic mastocytosis ( <i>off-label</i> ) Fracture prevention - breast/prostate cancer ( <i>off-label</i> )	

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
pamidronate	MM Bone metastasis from breast cancer Hypercalcemia of malignancy Systemic mastocytosis ( <i>off-label</i> ) Fracture prevention – breast/prostate cancer ( <i>off-label</i> )	
<b>Oral bisphosphonates</b>		
alendronate (Fosamax <sup>®</sup> )	Treatment: PMO Treatment: GIO, male osteoporosis	Varies <i>See prescribing information and compendia for dosing.</i>
Fosamax <sup>®</sup> Plus D (alendronate / cholecalciferol)	Treatment: PMO, male osteoporosis	
risedronate (Actonel <sup>®</sup> , Atelvia <sup>®</sup> )	<u>Actonel:</u> Treatment: PMO, GIO Treatment: male osteoporosis <u>Atelvia:</u> Treatment: PMO	
ibandronate (Boniva <sup>®</sup> )	Treatment/prevention: PMO	

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, and denosumab-dssb: hypocalcemia, pregnancy, known hypersensitivity to denosumab products
  - Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, and denosumab-bnht: hypocalcemia, known clinically significant hypersensitivity to denosumab products
- Boxed warning(s):
  - Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, and denosumab-bnht: none reported
  - Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, and denosumab-dssb:
    - Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, and denosumab-dssb administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
    - The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia.
    - Prior to initiating Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, and denosumab-dssb in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Prolia, Conexxence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, and denosumab-dssb in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD.



*Appendix D: IV/PO Bisphosphonates: Examples of Contraindications and Adverse Effects*

Bisphosphonates	Oral Formulations	IV Formulations
<b><i>Contraindications</i></b>		
Hypocalcemia	X	X
Increased risk of aspiration	X	-
Hypersensitivity to product component	X	X
Inability to stand/sit upright for at least 30 minutes	X	-
Creatinine clearance < 35 mL/min or evidence of acute renal impairment	-	X
Esophagus abnormalities which delay emptying such as stricture or achalasia	X	-
<b><i>Clinically significant warnings or adverse side effects</i></b>		
Pregnancy	X	X
Eye inflammation	X	X
Acute renal failure	X	X
Osteonecrosis of the jaw	X	X
Atypical femoral shaft fracture	X	X
Drug interactions (product-specific)	X	X
Severe or incapacitating musculoskeletal pain	X	X

*Appendix E: States with Regulations against Redirections in Stage III, IV or Metastatic Cancer*

State	Step Therapy Prohibited?	Notes
FL	Yes	For stage 4 metastatic cancer and associated conditions.
GA	Yes	For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.
IA	Yes	For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.
LA	Yes	For stage 4 advanced, metastatic cancer or associated conditions. Exception if “clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.
MS	Yes	<i>*Applies to HIM requests only*</i> For advanced metastatic cancer and associated conditions
NV	Yes	Stage 3 and stage 4 cancer patients for a prescription drug to treat the cancer or any symptom thereof of the covered person
OH	Yes	<i>*Applies to Commercial and HIM requests only*</i> For stage 4 metastatic cancer and associated conditions
OK	Yes	<i>*Applies to HIM requests only*</i> For advanced metastatic cancer and associated conditions
PA	Yes	For stage 4 advanced, metastatic cancer
TN	Yes	For advanced metastatic cancer and associated conditions
TX	Yes	For stage 4 advanced, metastatic cancer and associated conditions

*Appendix F: General Information*

- Bone Mineral Density (BMD) T-score was established by the World Health Organization (WHO) as the operational definition for post-menopausal osteoporosis. The T-score is the standard deviation of an individual's BMD from the mean value for young normal women. A normal T-score is considered -1.0 or above.
- The 2020 American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines use the T-score to diagnosis postmenopausal women with osteoporosis. When an individual's T-score is -2.5 or below, the individual is considered to have osteoporosis or severe osteoporosis in the presence of a fragility fracture (i.e., a fracture sustained from force similar to a fall from a standing position or less that would not have occurred in healthy bone).

**V. Dosage and Administration**

Drug Name	Indication	Dosing Regimen	Maximum Dose
Denosumab (Prolia, Conexence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, denosumab-dssb)	Treatment: PMO, GIO, male osteoporosis	60 mg SC once every 6 months	60 mg/dose
	Oncology: fracture prevention - Men at high risk for fracture receiving ADT for nonmetastatic prostate cancer - Women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer		
Denosumab (Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, denosumab-bnht)	MM Solid tumor - bone metastasis	120 mg SC once every 4 weeks	20 mg/dose
	Giant cell tumor of bone Hypercalcemia of malignancy	120 mg SC every 4 weeks plus 120 mg on Days 8 and 15 of first month of therapy	120 mg/dose

**VI. Product Availability**

Drug Name	Availability
Denosumab (Prolia, Conexence, Jubbonti, Ospomyv, Stoboclo, denosumab-bnht, denosumab-dssb)	Injection (single-use prefilled syringe): 60 mg/mL
Denosumab (Xgeva, Bomynta, Osenvelt, Wyost, Xbryk, denosumab-bnht)	<ul style="list-style-type: none"> <li>• Injection (single-use vial): 120 mg/1.7 mL (70 mg/mL)</li> <li>• <i>Bomynta and denosumab-bnht only</i> – Injection (single-dose prefilled syringe): 120 mg/1.7 mL (70 mg/mL)</li> </ul>

## VII. References

1. Prolia Prescribing Information. Thousand Oaks, CA: Amgen Inc.; March 2024. Available at: <http://www.prolia.com>. Accessed November 4, 2024.
  2. Jubbonti Prescribing Information. Princeton, NJ: Sandoz Inc.; October 2024. Available at: <http://www.jubbonti.com>. Accessed November 4, 2024.
  3. Xgeva Prescribing Information. Thousand Oaks, CA: Amgen Inc.; June 2020. Available at: <http://www.xgeva.com>. Accessed November 4, 2024.
  4. Wyost Prescribing Information. Princeton, NJ: Sandoz Inc.; March 2024. Available at: <http://www.wyost.com>. Accessed November 4, 2024.
  5. Ospomyv Prescribing Information. Incheon, Republic of Korea: Samsung Bioepis Co., Ltd.; February 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761392Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761392Orig1s000lbl.pdf). Accessed March 4, 2025.
  6. Xbryk Prescribing Information. Incheon, Republic of Korea: Samsung Bioepis Co., Ltd.; February 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761392Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761392Orig1s000lbl.pdf). Accessed March 4, 2025.
  7. Denosumab-dssb Prescribing Information. Incheon, Republic of Korea: Samsung Bioepis Co., Ltd.; February 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761392Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761392Orig1s000lbl.pdf). Accessed March 4, 2025.
  8. Stoboclo Prescribing Information. Jersey City, NJ: Celltrion USA, Inc.; February 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761404s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761404s000lbl.pdf). Accessed March 6, 2025.
  9. Osenvelt Prescribing Information. Jersey City, NJ: Celltrion USA, Inc.; February 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761404s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761404s000lbl.pdf). Accessed March 6, 2025.
  10. Bomynta Prescribing Information. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761398Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761398Orig1s000lbl.pdf). Accessed April 14, 2025.
  11. Conexence Prescribing Information. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761398Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761398Orig1s000lbl.pdf). Accessed April 14, 2025.
  12. Denosumab-bnht Prescribing Information. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2025. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/761398Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761398Orig1s000lbl.pdf). Accessed April 14, 2025.
  13. Clinical Pharmacology [database online]. Tampa, FL: Elsevier. 2023. URL: [www.clinicalkeys.com/pharmacology](http://www.clinicalkeys.com/pharmacology).
- Osteoporosis Diagnosis, Fracture Risk, and Treatment*
14. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab; March 2020, 105(3): 587-594.

15. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*; 2019, 104: 1595–1622.
16. Camacho PM, Petak SM, Brinkley N et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. *Endocr Pract*. 2020;26(1):1-46..
17. LeBoggs MS, Greenspan SL, Insongna KL, et al. Clinician’s guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2022 Oct;33(10):2049-2102. doi:10.1007/s00198-021-05900-y. Erratum in: *Osteoporos Int*. 2022 Jul 28.
18. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. *Osteoporos Int* (2014) 25:1439–1443. DOI 10.1007/s00198-014-2655-z.
19. Hodsman AB, Bauder DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. *Endocr Rev*. 2005 Aug;26(5):688-703. Epub 2005 Mar 15.
20. Qaseem A, Hicks LA, Etzeandia-Ikobaltzeta I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians (Version 1, Update Alert). *Ann Intern Med*. 2024 Jun; 177(6): eL230113.

Male Osteoporosis

21. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guidelines. *J Clin Endocrinol Metab* 2012;97(6):1802-1822.

Glucocorticoid-Induced Osteoporosis

22. Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheumatol*. 2023 Oct 16. doi:10.1002/art.42646. Epub ahead of print. PMID:37845798.

Oncology

23. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [www.nccn.org](http://www.nccn.org). Accessed November 4, 2024.
24. National Comprehensive Cancer Network. Multiple Myeloma Version 1.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf). Accessed November 4, 2024.
25. National Comprehensive Cancer Network. Bone Cancer Version 1.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/bone.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf). Accessed November 4, 2024.
26. National Comprehensive Cancer Network. Breast Cancer Version 5.2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed November 4, 2024.
27. National Comprehensive Cancer Network. Prostate Cancer Version 4.2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed November 4, 2024.
28. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version 11.2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed November 4, 2024.

29. National Comprehensive Cancer Network. Kidney Cancer Version 2.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf). Accessed November 4, 2024.
30. National Comprehensive Cancer Network. Systemic Mastocytosis Version 3.2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/mastocytosis.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mastocytosis.pdf). Accessed November 4, 2024.
31. National Comprehensive Cancer Network. Thyroid Carcinoma Version 4.2024. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed November 4, 2024.

### Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0897	Injection, denosumab, 1 mg
Q5136	Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2021 annual review: no significant changes; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	10.26.20	02.21
For prostate/breast cancer - fracture prevention, multiple myeloma, or solid tumor, and systemic mastocytosis: allowed bypassing of redirection if state regulations do not allow step therapy in Stage IV or metastatic cancer settings.	06.15.21	
Added Nevada to Appendix E.	08.03.21	
1Q 2022 annual review: updated definition of very high risk for fracture based on 2020 AACE/ACE PMO guidelines; references reviewed and updated.	10.02.21	02.22
For osteoporosis added option (in addition to contraindications or adverse effects) to bypass bisphosphonate trial if member has experienced a loss of BMD, lack of BMD increase, or has had an osteoporotic fracture or fragility fracture while receiving bisphosphonate therapy.	02.07.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.12.22	
1Q 2023 annual review: no significant changes, reference reviewed and updated.	10.28.22	02.23
Updated Appendix E to include Oklahoma.	06.07.23	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2024 annual review: no significant changes; for osteoporosis initial criteria, clarified “failure” of generic alendronate is preferred; references reviewed and updated.	10.23.23	02.24
RT4: added new biosimilars Jubbonti and Wyost to policy; added Appendix F to provide clarity on the interpretation of bone mineral density T-scores.	03.14.24	
Updated Appendix E to include Mississippi.	06.05.24	
Added HCPCS code [Q5136].	08.07.24	
1Q 2025 annual review: per updated prescribing information for Prolia and Jubbonti added boxed warnings for severe hypocalcemia in patients with advanced kidney disease; for prostate and breast cancer added requirement that member does not have bone metastasis; for giant cell tumor of bone localized disease removed option for combination use with interferon alfa per NCCN; references reviewed and updated.	10.22.24	02.25
RT4: added new biosimilars denosumab-dssb, Osenvelt, Ospomyv, Stoboclo, and Xbryk to criteria.	03.06.25	
RT4: added new biosimilars denosumab-bnht, Bomynta, and Conexence to criteria.	04.14.25	

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to



applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.